Cue Biopharma Inc (NAS:CUE)
$ 1.62 -0.03 (-1.82%) Market Cap: 78.80 Mil Enterprise Value: 52.23 Mil PE Ratio: 0 PB Ratio: 2.61 GF Score: 52/100

Q2 2021 Cue Biopharma Inc Earnings Call Transcript

Aug 17, 2021 / 08:30PM GMT
Release Date Price: $10.32 (+1.57%)
Operator

Greetings, and welcome to the Cue Biopharma Second Quarter 2021 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Dr. George Zavoico. Thank you, George. You may begin.

George B. Zavoico
Cue Biopharma, Inc. - VP of IR & Corporate Development

Thanks, Paul, and good afternoon, everyone. Thank you for joining us. On today's call are Dan Passeri, Cue Biopharma's CEO; and Dr. Anish Suri, President and Chief Scientific Officer; Dr. Ken Pienta, Acting Chief Medical Officer; Dr. Matteo Levisetti, Senior Vice President of Clinical Development; and Kerri-Ann Millar, Chief Financial Officer.

Before I begin, I would like to remind you that various remarks that the company makes during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot